BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

FemHealth Focus

EU Approves Daiichi Sankyo and AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive diseas...

October 28, 2026 | News

NTL HEALTHCARE Launches On-Premises AI Cervical Screening Platform to Strengthen Data Security

NTL HEALTHCARE, a women's health AI company, announced the global launch of CerviCARE® AI AT, an on-premises version of its AI-powered cervical screeni...

October 19, 2026 | News

IVI Institute Acquires The World Egg and Sperm Bank to Expand Global Fertility Care Network

IVI Institute, the global leader in fertility care, announced that The World Egg and Sperm Bank (TWESB), a trusted provider of donor egg and do...

October 19, 2026 | News

Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...

October 13, 2026 | News

Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer

Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...

October 06, 2026 | News

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...

September 25, 2026 | News

DKSH Launches Colpofix in Singapore to Support Women with HPV-Related Cervical Lesions

Women in Singapore now have another option to support their cervical health following Human Papillomavirus (HPV) infection, with DKSH's launch of Colpofix&...

September 22, 2026 | News

IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer

MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...

September 21, 2026 | News

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

Sorbent Enters Feminine Hygiene Market with Stayfree and Carefree Acquisition in Australia and New Zealand

Sorbent Paper Company Pty Ltd ("Sorbent") has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care b...

September 15, 2026 | News

Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...

September 15, 2026 | News

Hims & Hers Enters APAC Market with Australia Launch Following Eucalyptus Acquisition

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, announced it is now serving customers in Australia, marki...

September 03, 2026 | News

Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis

Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...

September 03, 2026 | News

US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...

August 27, 2026 | News

Stay Connected